Abstract: Herein is reported a feed mixing device for adding feed solutions with a non-physiologically pH value to a cell cultivation vessel comprising a chamber for mixing the feed solutions prior to their addition to the cell cultivation vessel as well as its use. With the feed mixing device as reported herein feed components can be provided in solution at a pH value at which they have good solubility and/or good stability whereby the pH value can be clearly different from the pH value of the cultivation medium, i.e. different from the physiological pH value. This allows performing the cultivation with more flexibility compared to a cultivation in which the pH value of the feed solution is limited to a small range around the pH value of the cultivation.

Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.

Abstract: A carrying strap (1) having a strap band (2) and at least one fastening device (4) for fastening a portable object (10), such as a camera, for example. At least one first rapid closure element (5) is fastened to the strap band (2), said element being a constituent part of a rapid closure mechanism which comprises the first (5) and a corresponding second rapid closure element (6). The first rapid closure element (5) can be released from the corresponding second rapid closure element (6) along a first direction (X) from a locking position, in which the second rapid closure element (6) is locked with the first rapid closure element (5), and can be brought into the locking position along a second direction (Y).

Abstract: An image analysis method for analyzing an IHC tissue sample includes storing, for each of one or more sets of digital images, a set-ID in a spatial database of a spatial DBMS, the images of each set depicting the same or adjacent layers of the IHC tissue sample; storing, for each of the, a plurality of spatial data objects in the database in association with the set-ID; creating, by the spatial DBMS, at least one spatial index covering the objects of the images contained in the one or more sets; applying, by the spatial DBMS, a spatial database operation on the at least one spatial index for determining the relative positions of objects of two or more images of a selected set; and providing the relative positions as input for determining the distance and/or relative position of the biomedical features of the tissue sample.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.

Abstract: For the removal of high molecular weight compounds from recombinantly produced polypeptides generally chromatographic methods are employed. It has been found that underivatized controlled pore glass (uCPG) selectively binds high molecular weight compounds present in a solution. The purified polypeptide can be recovered e.g. from the flow through of a chromatography column containing uCPG as chromatography material. It has been found that this effect is pronounced at a pH value of about 4 to 6 in buffered solutions. With approximately 100 m2 to 150 m2 uCPG surface per g of polypeptide almost 80% to 95% of the high molecular weight compounds are removed with a yield of 80% to 90% of polypeptide.

Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.

Abstract: Separating apparatus, comprising a sedimentation settler and a collection vessel disposed underneath and being in fluid communication with the sedimentation settler, the collection vessel forming a receiving chamber having an outlet at or adjacent to the chamber bottom and having an inlet opening, wherein the collection vessel is arranged such the flow direction of the fluid in the area underneath the sedimentation settler is substantially in line with the direction of the channels of the sedimentation settler.

Abstract: An apparatus and a method for cryopreserving a plurality of cellular samples are disclosed. The apparatus may include a cooling chamber and a cooling device that may include a mechanism to cool an interior of the cooling chamber. The cooling device may further include cooling tubes that are separate from the mechanism to cool the interior of the cooling chamber and that are arranged within the cooling chamber. The cooling device may provide a flow of refrigerant through the cooling tubes and a support for supporting a plurality of vials for storing cellular samples. The support may be movable relative to the cooling tubes such that the plurality of vials may be engageable with the cooling tubes.

Abstract: In the present invention a method for purifying erythropoietin comprising at least one chromatography step using a stationary phase containing hydroxyapatite is reported. The method comprises the following steps i) the erythropoietin in a solution containing Calcium-ions is brought into contact with a stationary phase containing hydroxyapatite equilibrated with a solution containing Calcium-ions and namely under conditions under which the erythropoietin binds to the stationary phase containing hydroxyapatite, ii) a solution is passed over the stationary phase containing hydroxyapatite from i) which contains less Calcium-ions than the previous solution and the erythropoietin is not detached from stationary phase containing hydroxyapatite, and iii) a further solution which contains less than 0.5 mM Calcium-ions is passed over the stationary phase containing hydroxyapatite from ii) whereby the erythropoietin is detached from the stationary phase containing hydroxyapatite.

Abstract: Compounds of formula (I) wherein R1, R2, A, W, m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.

Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.

Abstract: The invention provides novel compounds having the general formula (I) wherein RA, RB, RC, RC1 and W are as defined herein, compositions including the compounds and methods of using the compounds.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: The invention relates to a method for producing a friction lining material as well as a friction lining material having a porous body, whose pores are filled with a filling material, said porous body being formed on the basis of petroleum coke.

Abstract: A wafer holder is provided for use in a polishing machine. The wafer holder has a frame composed of a thermoset material and/or a thermoplastic material. The frame has at least one cavity for receiving and supporting a wafer to be polished in the polishing machine. A polymer film pad is permanently affixed in the at least one cavity.

Abstract: Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.

Abstract: A filter housing can support filter media for a fan arrangement. The filter housing can include a filter body with a first opening at a first end and a second opening at a second end. A bell portion can be disposed between the air inlet opening and the air outlet opening and can define a cavity within the housing body. An air-permeable filter support can extend into the cavity to support the filter media within the cavity, with the filter media spaced apart from at least one of the first and second openings.

Abstract: Embodiments of the invention provide a system and a method for mounting a panel within an enclosure. Using one or more sets of mounting blocks, the panel and a frame of the enclosure can be secured together in respective horizontal orientations, then collectively rotated to a vertical orientation. The one or more sets of mounting blocks can include a set of stop blocks, each including a respective tongue, and a set of slide blocks, each defining a respective recess when seated on a frame member of the enclosure frame. Each tongue can be configured to nest within a corresponding recess when the mounting blocks secure the panel to a corresponding frame member.